Company Filing History:
1 out of 2,893 
1 out of 1,929 
1 out of 11 Years Active: 1998-2015
Title: Innovations of Paul S. Fishman
Introduction
Paul S. Fishman is a notable inventor based in Baltimore, MD, with a significant contribution to the field of neurotoxin research. He holds four patents that focus on methods for identifying inhibitors of botulinum neurotoxins. His work has implications for medical and therapeutic applications, particularly in understanding and mitigating the effects of neurotoxins.
Latest Patents
Fishman's latest patents include innovative systems and methods for identifying botulinum neurotoxin inhibitors. One of his patents describes a method employing a botulinum neurotoxin substrate complex that utilizes a peptide substrate, preferably SNAP-25. This complex features a reporter domain on one side and an immobilization domain on the opposite side of the peptide substrate. The effectiveness of the neurotoxin inhibitor is determined by its ability to reduce the amount of cleaved complex, which is measured by a decrease in the complex bound to a solid support. Additionally, his methods utilize novel cells that express a botulinum neurotoxin substrate complex, along with stable cell lines and viral vectors that can efficiently express an active light chain of the botulinum neurotoxin within mammalian cells.
Career Highlights
Throughout his career, Paul S. Fishman has worked with various organizations, including The General Hospital Corporation. His research has significantly advanced the understanding of neurotoxin interactions and potential inhibitors, contributing to the broader field of biomedical research.
Collaborations
Fishman has collaborated with notable colleagues such as Randall L. Kincaid and George A. Oyler. These collaborations have likely enriched his research and contributed to the development of his innovative patents.
Conclusion
Paul S. Fishman is a distinguished inventor whose work on botulinum neurotoxin inhibitors has the potential to impact medical science significantly. His patents reflect a commitment to advancing research in neurotoxin interactions and therapeutic solutions.